Silicon Valley Capital Partners’s Amphastar Pharmaceuticals AMPH Stock Holding History

Silicon Valley Capital Partners’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-229	Closed	-$8.5K	–	251
2024 Q4	$8.5K	Hold	229	–	–	﹤0.01%	265
2024 Q3	$11.1K	Hold	229	–	–	﹤0.01%	242
2024 Q2	$9.16K	Hold	229	–	–	﹤0.01%	249
2024 Q1	$10.1K	Hold	229	–	–	﹤0.01%	233
2023 Q4	$14.2K	Hold	229	–	–	﹤0.01%	220
2023 Q3	$10.5K	Hold	229	–	–	﹤0.01%	189
2023 Q2	$13.2K	Buy	+229	New	+$10.2K	﹤0.01%	177

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silicon Valley Capital Partners's AMPH Position: Q1 2025 in Review

Silicon Valley Capital Partners sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2025, closing a stake of 229 shares — an estimated $8.5K sold.

Silicon Valley Capital Partners first reported a position in AMPH in Q2 2023 and held it in 7 quarters. The position peaked at $14.2K in Q4 2023. 241 funds tracked by Wall St. Rank hold AMPH as of Q1 2025.

Silicon Valley Capital Partners reported no remaining Amphastar Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Silicon Valley Capital Partners sold 229 Amphastar Pharmaceuticals shares in Q1 2025, an estimated $8.5K.
Silicon Valley Capital Partners first reported a position in Amphastar Pharmaceuticals in Q2 2023 and held it in 7 quarters.
Silicon Valley Capital Partners's Amphastar Pharmaceuticals position peaked at $14.2K in Q4 2023.
241 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2025.

Based on Silicon Valley Capital Partners's 13F filing for Q1 2025, filed 28 May 2025.